Head-To-Head Contrast: Shuttle Pharmaceuticals (NASDAQ:SHPH) versus Tempest Therapeutics (NASDAQ:TPST)

Tempest Therapeutics (NASDAQ:TPST) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Risk & Volatility

Tempest Therapeutics has a beta of -2.41, suggesting that its share price is 341% less volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -0.81, suggesting that its share price is 181% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Tempest Therapeutics and Shuttle Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1	2	0	0	1.67
Shuttle Pharmaceuticals	1	0	0	0	1.00

Tempest Therapeutics currently has a consensus price target of $12.50, indicating a potential upside of 465.61%. Given Tempest Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Tempest Therapeutics is more favorable than Shuttle Pharmaceuticals.

Insider & Institutional Ownership

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 6.3% of Tempest Therapeutics shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Tempest Therapeutics and Shuttle Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$41.84 million	($10.05)	-0.22
Shuttle Pharmaceuticals	N/A	N/A	-$9.15 million	($11.84)	-0.09

Tempest Therapeutics is trading at a lower price-to-earnings ratio than Shuttle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tempest Therapeutics and Shuttle Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-310.89%	-125.12%
Shuttle Pharmaceuticals	N/A	-476.10%	-253.93%

Summary

Tempest Therapeutics beats Shuttle Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Tempest Therapeutics

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.